Barclays PLC Geron Corp Put Options Transaction History

Barclays PLC

4 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2018 Nov 14, 2018	BUY	$1.76 - $6.38 $71,280 - $258,390	40,500 Added 84.55%	88,400 $156,000
Q2 2018 Aug 14, 2018	BUY	$3.29 - $4.82 $151,011 - $221,238	45,900 Added 2295.0%	47,900 $164,000
Q4 2017 Feb 14, 2018	SELL	$1.8 - $2.32 $39,240 - $50,576	-21,800 Reduced 91.6%	2,000 $4,000
Q3 2017 Nov 14, 2017	BUY	$1.99 - $2.65 $47,362 - $63,070	23,800	23,800 $52,000

306

465M

1.07M

648K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $971M
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.